Pharma stocks on Friday reeled under pressure on fears that the duty entitlement passbook (DEPB) benefits scheme may be withdrawn from the exporting companies, thus, hurting their overseas formulations.
Chirag Talati, analyst at Espirito Santo Securities Pharma, in an interview with CNBC-TV18's Udayan Mukherjee, spoke about the dark cloud of penalty hanging over Ranbaxy, and how DEPB credit can affect Dr Reddy
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
